STAT3 and non-small cell lung carcinoma: Additionally, a recent research revealed the therapeutic applicability and efficacy of targeting STAT3 to inhibit CAF-NSCLC cell crosstalk using STAT3 siRNA delivery targeted systems based on nucleic acid aptamers as carriers.